What is the purpose of this clinical trial?

Gastroesophageal cancers, meaning cancers in the esophagus (food pipe) and/or stomach, remain a leading cause of death worldwide despite recent advances. Many patients eventually develop resistance to current standard treatments. There is an urgent need for new targeted/personalized therapies to help improve long-term survival and provide better options for those whose cancer has progressed.

The Symbiotic-GI-16 clinical trial is evaluating a study medicine, given with standard chemotherapy treatment, in people with locally advanced or metastatic stomach and/or esophageal cancer. Your physician will decide which chemotherapy treatment plan is best for you (one of two standard of care chemotherapy treatment plans) and will tell you what you are receiving.

The study medicine is a bispecific antibody designed to target two different proteins, PD-1 and VEGF, at the same time. These proteins can play a role in how the cancer grows and how the immune system responds to it. It is thought that by binding (or connecting) to these two proteins, the study medicine may help the immune system find and attack the cancer cells while also potentially slowing down tumor growth, which may be more effective for treating gastroesophageal cancer.

Your journey and your choice

Participant safety is the top priority of this clinical trial. Before you participate, you will be given all the details about the clinical trial, including potential benefits and risks of taking part. Your health will also be monitored by the study team while in the study.

If this clinical trial is a good fit for you and you decide to take part, it's important to remember that this is your journey and choice. You are free to stop being in this clinical trial at any time for any reason.

Are you ready to take the next step?

For more information, reach out to our study team.

You can also visit **PfizerStudyforGI.com** or scan the QR code for more information.

Pfizer Symbiotic-GI-16

C6461016_Study Brochure_US EN_V1_10Feb26

Help drive advancements in gastroesophageal cancer research

Read about the Symbiotic-GI-16 clinical trial for people with gastroesophageal (upper GI) cancer

Gastroesophageal Cancer | C6461016

Pfizer Symbiotic-GI-16

Study overview

Study treatment

The study medicine is given as intravenous (IV) infusions, meaning directly into the bloodstream through a small tube inserted into a vein. The chemotherapy treatment plan (every 2 weeks or 3 weeks) will be decided by the study doctor based on your cancer and your health.

Study duration

The length of this clinical trial depends on how long you receive the study treatment and have follow-up visits. You may continue to take the study treatment for as long as the clinical trial is open and your cancer is stable or has improved, or until the trial doctor decides to stop treatment. You may choose to stop taking the study treatment and leave the clinical trial at any time.

Participation costs

The study treatment and all assessments that are not a part of your regular medical care will be provided at no cost. You may also have some trial-related costs paid back, like travel and hotel stays. Participants do not need health insurance to take part.

Who can participate?

You may be eligible to participate in this clinical trial if you are aged 18 or older and:

- Have been diagnosed with locally advanced or metastatic stomach and/or esophageal cancer
- Have not received prior treatment for advanced or metastatic cancer
- Your tumor has been diagnosed as “HER2-negative” and “PD-L1 positive” *

*These cancer biomarkers are specific proteins, genes, or other markers that can give you more information about your cancer.

What to expect

Screening Period - up to 28 days

- You will need to sign the Informed Consent Document before you can begin the Screening Period.
- You will have at least 1 visit where the study doctor will determine if you are eligible to take part.

Treatment Period

- You will have clinic visits every 2 or 3 weeks (depending on which chemotherapy plan your doctor chooses).
- You will have assessments at each visit, which may include physical exams, blood/urine tests, questionnaires, electrocardiograms, and tumor imaging scans. Your doctor can answer any questions you may have.

End of Treatment Visit

- You will have 1 visit about 4 to 5 weeks after your last dose to monitor your health and cancer after taking the study treatment.

Follow-up Period

- All participants will have a follow-up visit or phone call every 12 weeks after the end of treatment visit to monitor the potential effects and side effects of the study medicine over time.